TEVA - Neurocrine Biosciences Trading Near Its 52-Week Low As Delta Threatens The Ingrezza Rebound

• Neurocrine posted better than expected sales in the second quarter, with a much-needed beat for Ingrezza sales, but the resurgence of COVID-19 infections threatens to unravel that progress.
• Ingrezza prescriptions really depend upon face-to-face visits with prescribing physicians, and COVID-19 restrictions further hamper the company's sales and physician education efforts.
• Management will test Ingrezza in two additional Phase III programs; a high-risk study of Ingrezza as an adjunctive treatment for schizophrenia and a study in dyskinetic cerebal palsy.
• While Neurocrine has a promising pipeline, major data isn't coming soon and the Street wants to see Ingrezza back on a reliable growth path before returning to the stock.

For further details see: